Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass.
Gaillard DHK, Lof P, Sistermans EA, Mokveld T, Horlings HM, Mom CH, Reinders MJT, Amant F, van den Broek D, Wessels LFA, Lok CAR; HE4 Study Group; Study group. Gaillard DHK, et al. Among authors: van den broek d. Int J Gynecol Cancer. 2024 May 6;34(5):713-721. doi: 10.1136/ijgc-2023-005073. Int J Gynecol Cancer. 2024. PMID: 38388177
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
van Veggel BAMH, van der Wekken AJ, Paats MS, Hendriks LEL, Hashemi SMS, Daletzakis A, van den Broek D, Bosch LJW, Monkhorst K, Smit EF, de Langen AJ. van Veggel BAMH, et al. Among authors: van der wekken aj, van den broek d. Cancer. 2024 Mar 1;130(5):683-691. doi: 10.1002/cncr.35090. Epub 2023 Oct 31. Cancer. 2024. PMID: 37905752 Clinical Trial.
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.
Rozeman EA, Versluis JM, Sikorska K, Hoefsmit EP, Dimitriadis P, Rao D, Lacroix R, Grijpink-Ongering LG, Lopez-Yurda M, Heeres BC, van de Wiel BA, Flohil C, Sari A, Heijmink SWTPJ, van den Broek D, Broeks A, de Groot JWB, Vollebergh MA, Wilgenhof S, van Thienen JV, Haanen JBAG, Blank CU. Rozeman EA, et al. Among authors: van de wiel ba, van thienen jv, van den broek d. J Immunother Cancer. 2023 Jul;11(7):e006821. doi: 10.1136/jitc-2023-006821. J Immunother Cancer. 2023. PMID: 37479483 Free PMC article. Clinical Trial.
A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice.
Kramer A, Schuuring E, Vessies DCL, van der Leest P, Geerlings MJ, Rozendal P, Lanfermeijer M, Linders TC, van Kempen LC, Fijneman RJA, Ligtenberg MJL, Meijer GA, van den Broek D, Retèl VP, Coupé VMH; COIN Consortium. Kramer A, et al. Among authors: van kempen lc, van den broek d, van der leest p. J Mol Diagn. 2023 Jan;25(1):36-45. doi: 10.1016/j.jmoldx.2022.10.004. Epub 2022 Nov 17. J Mol Diagn. 2023. PMID: 36402278 Free article.
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.
van Dorp J, Pipinikas C, Suelmann BBM, Mehra N, van Dijk N, Marsico G, van Montfoort ML, Hackinger S, Braaf LM, Amarante T, van Steenis C, McLay K, Daletzakis A, van den Broek D, van de Kamp MW, Hendricksen K, de Feijter JM, Boellaard TN, Meijer RP, van der Heijden AG, Rosenfeld N, van Rhijn BWG, Jones G, van der Heijden MS. van Dorp J, et al. Among authors: van montfoort ml, van steenis c, van rhijn bwg, van den broek d, van de kamp mw, van der heijden ag, van der heijden ms, van dijk n. Nat Med. 2023 Mar;29(3):588-592. doi: 10.1038/s41591-022-02199-y. Epub 2023 Feb 2. Nat Med. 2023. PMID: 36732628 Clinical Trial.
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC.
Jebbink M, de Langen AJ, Monkhorst K, Boelens MC, van den Broek D, van der Noort V, de Gooijer CJ, Mahn M, van der Wekken AJ, Hendriks L, Hashemi SMS, Paats MS, Dingemans AC, Smit EF. Jebbink M, et al. Among authors: van der wekken aj, van den broek d, van der noort v. JTO Clin Res Rep. 2023 Feb 24;4(4):100481. doi: 10.1016/j.jtocrr.2023.100481. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37035409 Free PMC article.
97 results